Observational study on epilepsy in western Sweden
Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment
This study looks at adults in western Sweden who have had seizures or epilepsy to see if there are specific markers or genes that can help with their diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sahlgrenska University Hospital Academic / other |
| Locations | 3 sites (Borås and 2 other locations) |
| Trial ID | NCT04559919 on ClinicalTrials.gov |
What this trial studies
This observational study follows adults with an unprovoked seizure or epilepsy in western Sweden to identify biomarkers and genetic predispositions relevant for diagnosis and treatment. It collects baseline data and outcome variables from various patient registries, including electronic medical records and national health registers. The aim is to understand the long-term prognosis and consequences of epilepsy in this population.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years of age who have experienced an unprovoked seizure in the last year or have a diagnosis of epilepsy.
Not a fit: Patients with expected survival of less than two years or those unable to give informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment options for patients with epilepsy.
How similar studies have performed: Other studies have shown success in identifying biomarkers for epilepsy, making this approach promising yet still requiring further exploration.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Over 18 years of age * An unprovoked seizure within the last year or a diagnosis of epilepsy according to the current International League Against Epilepsy definition (epilepsy with seizure in the last ten or antiepileptic drug treatment in the last five years) Exclusion Criteria: * Expected survival less than two years * Inability to give informed consent
Where this trial is running
Borås and 2 other locations
- Södra Älvsborgs Sjukhus — Borås, Sweden (Recruiting)
- Sahlgrenska University Hospital — Gothenburg, Sweden (Recruiting)
- Sjukhusen i Väster — Gothenburg, Sweden (Recruiting)
Study contacts
- Principal investigator: Johan Zelano, MD PhD — Sahlgrenska University Hospital
- Study coordinator: Johan Zelano, MD PhD
- Email: johan.zelano@vgregion.se
- Phone: +46313421000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.